Patents Represented by Attorney, Agent or Law Firm Richard L. Neeley
  • Patent number: 6805842
    Abstract: A sample container for minimizing evaporation of a contained volume of sample includes a container housing, a repuncturable self-sealing membrane, and a collapsible sample bag. The container housing includes an open end and a hollow interior region. The repuncturable self-sealing membrane configured to self-seal after repeated punctures is engaged in the open end of the container housing and includes an exterior surface exposed to the external environment and an interior surface oriented toward the hollow interior region of the container housing. The collapsible sample bag includes a proximate end that is permanently attached to the interior surface of the repuncturable self-sealing membrane.
    Type: Grant
    Filed: October 12, 2001
    Date of Patent: October 19, 2004
    Assignee: MDS Sciex
    Inventors: Kevin S. Bodner, Tyler A. Palmer, Pejman Ghanouni
  • Patent number: 6699294
    Abstract: A method for tissue augmentation in a mammal is provided comprising injecting a polymer at a tissue site in need of augmentation and having a tissue temperature, the polymer comprising repeating peptide monomeric units selected from the group consisting of nonapeptide, pentapeptide and tetrapeptide monomeric units, wherein the monomeric units form a series of &bgr;-turns separated by dynamic bridging segments suspended between the &bgr;-turns, wherein the polymer has an inverse temperature transition Tt less than the tissue temperature, and wherein the polymer is injected as a water solution at coacervate concentration in the substantial absence of additional water. A kit containing the injectable bioelastic polymer and a syringe is also provided.
    Type: Grant
    Filed: April 18, 2001
    Date of Patent: March 2, 2004
    Assignee: Bioelastics Research, Ltd.
    Inventor: Dan W. Urry
  • Patent number: 6565827
    Abstract: Methods for the treatment of lymphoma by administration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy.
    Type: Grant
    Filed: August 7, 2001
    Date of Patent: May 20, 2003
    Assignees: Coulter Pharmaceutical, Inc., The Regents of the University of Michigan
    Inventors: Mark S. Kaminski, Gregory M. Butchko, Stephan D. Glenn, Richard L. Wahl
  • Patent number: 6566079
    Abstract: The present invention provides a variety of methods of analyzing protein binding events using a system capable of directly detecting protein/ligand complexes based upon the dielectric properties of the complex. The system can be used in a variety of analyses involving protein binding events, such as screening ligand libraries, characterizing protein binding interactions, and identifying ligands. The system can also be utilized in diverse analytical and diagnostic applications.
    Type: Grant
    Filed: August 6, 2001
    Date of Patent: May 20, 2003
    Assignee: Signature BioScience, Inc.
    Inventor: John Hefti
  • Patent number: 6533819
    Abstract: A method for tissue augmentation in a mammal is provided having injecting a polymer at a tissue site in need of augmentation and having a tissue temperature, the polymer having repeating peptide monomeric units selected from the group consisting of nonapeptide, pentapeptide and tetrapeptide monomeric units, wherein the monomeric units form a series of &bgr;-turns separated by dynamic bridging segments suspended between the &bgr;-turns, wherein the polymer has an inverse temperature transition Tt less than the tissue temperature, and wherein the polymer is injected as a water solution at coacervate concentration in the substantial absence of additional water. A kit containing the injectable bioelastic polymer and a syringe is also provided.
    Type: Grant
    Filed: April 23, 2001
    Date of Patent: March 18, 2003
    Assignee: Bioelastics Research, Ltd.
    Inventors: Dan W. Urry, Timothy M. Parker, Paul A. Glazer
  • Patent number: 6376258
    Abstract: Systems and methods are presented for detecting molecular binding events and other environmental effects using the unique dielectric properties of the bound molecular structure or structures. A molecular binding region is coupled along the surface of a signal path. A test signal is propagated along the signal path, whereby the test signal couples to the molecular binding region, and in response, exhibits a signal response.
    Type: Grant
    Filed: January 10, 2000
    Date of Patent: April 23, 2002
    Assignee: Signature BioScience, Inc.
    Inventor: John Hefti
  • Patent number: 6368795
    Abstract: Systems and methods for detecting molecular binding events and other environmental effects using the unique dielectric properties of the bound molecular structure or structures are presented. A molecular binding layer is coupled along the surface of a signal path. A test signal is propagated along the signal path, whereby the test signal couples to the molecular binding layer, and in response, exhibits a signal response.
    Type: Grant
    Filed: February 1, 1999
    Date of Patent: April 9, 2002
    Assignee: Signature BioScience, Inc.
    Inventor: John Hefti
  • Patent number: 6338968
    Abstract: Systems and methods are presented for detecting molecular binding events and other environmental effects using the unique dielectric properties of the bound molecular structure or structures. A molecular binding region is coupled along the surface of a signal path. A test signal is propagated along the signal path, whereby the test signal couples to the molecular binding region, and in response, exhibits a signal response.
    Type: Grant
    Filed: August 2, 1999
    Date of Patent: January 15, 2002
    Assignee: Signature BioScience, Inc.
    Inventor: John Hefti
  • Patent number: 6328996
    Abstract: A drug delivery composition, comprising a bioelastic polymer, comprising monomeric units selected from the group consisting of bioelastic pentapeptides, tetrapeptides, and nonapeptides, and a drug retained by the polymer, wherein the polymer is selected to be in a first contraction state, selected from the group consisting of contracted and relaxed bioelastomer states, when contacted with a physiological condition present in a human or animal to whom the composition is administered and wherein the polymer contains a reactive functional group that undergoes a reaction, either in the presence of the physiological condition or when the polymer is transported by a natural process in the human or animal to a different location having a different physiological condition, to produce a second functional group, wherein the presence of the second functional group in the polymer causes the polymer to switch to the other of the contraction states, thereby making the drug available for release from the composition.
    Type: Grant
    Filed: October 3, 1994
    Date of Patent: December 11, 2001
    Assignees: Bioelastics Research Ltd., UAB Research Foundation
    Inventor: Dan W. Urry
  • Patent number: 6287874
    Abstract: The present invention provides a variety of methods of analyzing protein binding events using a system capable of directly detecting protein/ligand complexes based upon the dielectric properties of the complex. The system can be used in a variety of analyses involving protein binding events, such as screening ligand libraries, characterizing protein binding interactions, and identifying ligands. The system can also be utilized in diverse analytical and diagnostic applications.
    Type: Grant
    Filed: August 2, 1999
    Date of Patent: September 11, 2001
    Assignee: Signature BioScience, Inc.
    Inventor: John Hefti
  • Patent number: 6287776
    Abstract: The present invention provides a variety of methods for conducting analyses of nucleic acids using a detection system which is sensitive to the unique dielectric properties of different hybridization complexes and which can distinguish between different hybridization complexes directly without the use of labels. Methods using the system to perform sequence checking, expression analysis, de novo sequencing and a variety of other nucleic acid analyses are provided.
    Type: Grant
    Filed: August 2, 1999
    Date of Patent: September 11, 2001
    Assignee: Signature BioScience, Inc.
    Inventor: John Hefti
  • Patent number: 5891639
    Abstract: Telomerase activity in a sample can be measured using a two reaction protocol. The first reaction involves the formation of telomerase substrate extension products from a telomerase substrate. The second reaction involves replication of the telomerase substrate extension products and/or amplification of signal generated by a bound probe. The presence of telomerase activity in a human somatic tissue or cell sample is positively correlated with the presence of cancer and can be used to diagnose a disease or other conditions of medical interest, as well as the course of disease progression or remission in a patient.
    Type: Grant
    Filed: June 18, 1998
    Date of Patent: April 6, 1999
    Assignee: Geron Corporation
    Inventors: Calvin Bruce Harley, Nam Woo Kim, Scott Lawrence Weinrich
  • Patent number: 5863726
    Abstract: Telomerase activity in a sample can be measured using a two reaction protocol. The first reaction involves the formation of telomerase substrate extension products from a telomerase substrate. The second reaction involves replication of the telomerase substrate extension products and/or amplification of signal generated by a bound probe. The presence of telomerase activity in a human somatic tissue or cell sample is positively correlated with the presence of cancer and can be used to diagnose a disease or other conditions of medical interest, as well as the course of disease progression or remission in a patient.
    Type: Grant
    Filed: April 12, 1996
    Date of Patent: January 26, 1999
    Assignee: Geron Corporation
    Inventors: Calvin Bruce Harley, Nam Woo Kim, Scott Lawrence Weinrich
  • Patent number: 5840490
    Abstract: Methods for detecting hematologic and colorectal malignancies are provided comprising: (a) collecting a sample suspected of containing cancer cells; (b) analyzing the sample for telomerase activity; (c) correlating the presence of telomerase activity with the presence of cancer cells. A method for staging leukemia is also provided comprising analyzing a blood or bone marrow sample for telomerase activity, correlating the activity with a standard level of telomerase activity, and correlating a low telomerase activity with early stage leukemia.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 24, 1998
    Assignee: McMaster University
    Inventors: Silvia Bacchetti, Christopher M. Counter, Brian Leber, Calvin Bruce Harley
  • Patent number: 5837453
    Abstract: Telomerase activity in a sample can be measured using a two reaction protocol involving telomerase substrate and primer extension steps. The presence of telomerase activity in a human somatic tissue or cell sample is positively correlated with the presence of cancer and can be used to diagnose the course of disease progression in a patient.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 17, 1998
    Assignee: Geron Corporation
    Inventors: Calvin Bruce Harley, Nam Woo Kim, Scott Lawrence Weinrich
  • Patent number: 5804380
    Abstract: Telomerase activity in a sample can be measured using a two reaction protocol. The first reaction involves the formation of telomerase substrate extension products from a telomerase substrate. The second reaction involves replication of the telomerase substrate extension products and/or amplification of signal generated by a bound probe. The presence of telomerase activity in a human somatic tissue or cell sample is positively correlated with the presence of cancer and can be used to diagnose a disease or other conditions of medical interest, as well as the course of disease progression or remission in a patient.
    Type: Grant
    Filed: April 15, 1996
    Date of Patent: September 8, 1998
    Assignee: Geron Corporation
    Inventors: Calvin Bruce Harley, Nam Woo Kim, Scott Lawrence Weinrich
  • Patent number: 5705342
    Abstract: The invention provides compositions and methods for screening for agents which are modulators of bcl-2 function and can modulate bcl-2-mediated apoptosis and/or modulate neoplastic and immune conditions dependent upon bcl-2 function. The invention also provides a composition comprising a substantially pure protein complex comprising a R-ras polypeptide and a bcl-2 polypeptide.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 6, 1998
    Assignee: Onyx Pharmaceuticals, Inc.
    Inventors: James R. Bischoff, Maria Jose Fernandez-Sarabia
  • Patent number: 5693474
    Abstract: A method for predicting tumor progression and prognosing cancer comprises: (a) collecting a sample suspected of containing cancer cells; (b) analyzing the sample for telomerase activity; (c) correlating the activity with a standard level of telomerase activity; and (d) correlating a high telomerase activity with an indication of unfavorable prognosis and a low telomerase activity with a favorable prognosis.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 2, 1997
    Assignee: Board of Regents, University of Texas System
    Inventors: Jerry Shay, Michael David West, Woodring E. Wright
  • Patent number: 5639613
    Abstract: A method for predicting tumor progression and prognosing cancer comprises: (a) collecting a sample suspected of containing cancer cells; (b) analyzing the sample for telomerase activity; (c) correlating the activity with a standard level of telomerase activity; and (d) correlating a high telomerase activity with an indication of unfavorable prognosis and a low telomerase activity with a favorable prognosis.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: June 17, 1997
    Assignee: Board of Regents, University of Texas System
    Inventors: Jerry Shay, Michael David West, Woodring E. Wright
  • Patent number: 5434052
    Abstract: Compounds are evaluated for their binding to naturally occurring receptors, by employing the natural ligand conjugated to an enzyme donor fragment of .beta.-galactosidase for competing with the sample compound for the natural acceptor binding site or in the absence of competition where the sample compound binds to an allosteric site. By adding the enzyme acceptor fragment of the .beta.-galactosidase and substrate, the binding affinity of the sample compound may be evaluated as a measure of agonist or antagonist capability.
    Type: Grant
    Filed: July 21, 1993
    Date of Patent: July 18, 1995
    Assignee: Microgenics Corporation
    Inventor: Pyare Khanna